Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenVec has announced that the first human therapeutic clinical trial involving the company's adenoviral-vector technology used in an HIV vaccine candidate will be conducted by the US National Institutes of Health's Vaccine Research Center.
Subscribe to our email newsletter
These will be the first human trials to assess the effectiveness of a ‘prime-boost’ vaccine using GenVec’s adenovector technology as a potential therapy for patients infected with HIV. The randomized, placebo-controlled study will measure safety and immunogenicity of the vaccine in 15 HIV positive patients.
The trial will combine two components, a DNA prime vaccine and GenVec’s adenovector-based technology used in the boost vaccine. The adenovector-based boost vaccine was developed using the company’s proprietary technology and 293-ORF6 cell line. Patients in the study will be treated with the first vaccine (known as DNA prime) followed by a booster with the second vaccine (known as rAD5 boost), and will be evaluated for 48 weeks.
The clinical trial will be conducted by the Vaccine Research Center as part of a broad effort to test HIV vaccines based on GenVec’s adenovector delivery technology and cell line.